



NEWS RELEASE

Incubate Bio announces new discovery pipeline of 70 potential oncology combination therapies

- *Pipeline will be ready for pre-clinical toxicology validation*
- *Combinations feature known assets from oncology players across the industry currently in development or in market*

London, November 23, 2023 - Following successful demonstration of its proprietary Causal AI capability ([more](#) details here), Incubate Bio is announcing a new discovery pipeline of potential oncology combination therapies targeting hard-to-treat cancers. Combination therapies that progress through this pipeline (<http://incubate.bio/pipeline>) will be ready for pre-clinical toxicology validation.

The expert team at Incubate Bio has executed a comprehensive programme, focused on small molecule oncology assets and their related targets, with the goal of identifying new combination therapies to address the unmet medical need of patients suffering from hard-to-treat cancers such as ovarian and pancreatic cancer. Our pipeline demonstrates the ability of our AI-driven drug discovery platform (ALaSCA) to rapidly identify actionable oncology combination therapy options.

These assets are currently being explored using Incubate Bio's proprietary ALaSCA technology combined with open access data. ALaSCA is able to identify both pathway resistance and necessary literature evidence, which together make the resulting outputs both meaningful and actionable.

New findings are being actively produced daily and these unique outputs are collated into focused reports which are available to companies and organizations across the life science sector. These data will be of utility for organisations looking to maximize the value of their portfolio, through strategic partnerships or product life cycle extensions.

Additional exploration of areas of specific interest to an organisation can be provided a bespoke services engagement. The ALaSCA approach has proven a useful tool for prioritisation of valuable wet lab resources during the drug discovery process ([more](#) details here) and for product commercial leads seeking new ideas to discuss with R&D.

+++ END +++

About Incubate Bio

Incubate Bio is pinpointing and validating the causal links between targets and cancer, using its proprietary ALASCA technology to inform pipeline decision making. Using pathway analysis to identify key drivers and supports for target discovery and identification - indication expansion & extension (repurposing), possible combination therapies and patent life-cycle management.

With a primary focus on oncology (specifically the DNA Damage Repair, DDR, pathway, synthetic lethality), we are generating unique in silico data packages containing characterised and prioritised targets and biomarkers with critical supporting evidence.

Applying rigorous causal AI mathematics developed over the last three decades into the target discovery space. We go beyond standard machine learning (ML) approaches and bioinformatics to provide the relevant evidence and intelligent data insights to comprehensively enhance biological multi-omics data. Interrogation of these biosignatures enhance understanding and ultimately enable identification of novel insights to inform and support pipeline decision making.

Founded and led by Dr Raminderpal Singh, a veteran corporate executive with extensive commercial partnering experience across the US and European life science ecosystems.

For more about Incubate bio: <https://www.incubate.bio/>